Literature DB >> 20466271

Infectious complications associated with immunomodulating biologic agents.

Sophia Koo1, Francisco M Marty, Lindsey R Baden.   

Abstract

The armamentarium of biologic therapies targeting specific elements of the immune system is rapidly expanding. This review describes the spectrum of infectious complications associated to date with each of the immunomodulating biologic therapies approved by the US Food and Drug Administration. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20466271     DOI: 10.1016/j.idc.2010.01.006

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  18 in total

1.  Histological characteristics of the abdominal aortic wall in patients with vascular chronic Q fever.

Authors:  Julia C J P Hagenaars; Olivier H J Koning; Ronald F F van den Haak; Bart A N Verhoeven; Nicole H M Renders; Mirjam H A Hermans; Peter C Wever; Robert Jan van Suylen
Journal:  Int J Exp Pathol       Date:  2014-06-23       Impact factor: 1.925

Review 2.  The occurrence and prevention of foodborne disease in vulnerable people.

Authors:  Barbara M Lund; Sarah J O'Brien
Journal:  Foodborne Pathog Dis       Date:  2011-05-11       Impact factor: 3.171

3.  Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab.

Authors:  Alissa J Wright; Theodore Steiner; Ana Maria Bilawich; John C English; C Frank Ryan
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis.

Authors:  Nagwa Mostafa El-Sayed; Khadiga Ahmed Ismail; Abeer Fathy Badawy; Khaled Fathy Elhasanein
Journal:  J Parasit Dis       Date:  2015-09-24

5.  Case Report: Histoplasma Hepatitis Presenting as Common Bile Duct Obstruction.

Authors:  Brittany Hjermstad; Dale Snover; Jose D Debes
Journal:  Am J Trop Med Hyg       Date:  2022-04-11       Impact factor: 3.707

6.  Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Authors:  Brett J Loechelt; Michael Green; Peter A Gottlieb; Emily Blumberg; Adriana Weinberg; Scott Quinlan; Lindsey R Baden
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-26       Impact factor: 3.164

7.  A new side of sarcoidosis: medication and hospitalization use in a privately insured patient population.

Authors:  Derek Low; Kit N Simpson; Richard Rissmiller; Ennis James
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 8.  HLA-B27 spondyloarthritis and spotted fever rickettsiosis: case-based review.

Authors:  Albert H Redford; Jaren R Trost; Wilmer L Sibbitt; Monthida Fangtham; N Suzanne Emil; Shalini Singh; Arthur D Bankhurst
Journal:  Rheumatol Int       Date:  2019-05-27       Impact factor: 3.580

Review 9.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

10.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.